17/2 tirzepatide dosing Chart: Weekly Guide to Safe Titration ✨ NEW PATIENT SPECIAL ✨

Atlas Men's Health represents a trusted leader in mens health solutions

A Brave New World Therapeutic Area Deep Dives on Obesity This blog is part of a series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1

GLP-1 Pipeline Update: August 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid

(1) SDT fatty rats given certified diet-experimental animal diet 2 (CE-2), a standard chow provided from CLEA (CLEA, Tokyo, Japan) (DKD-vehicle), (2) SDT fatty rats given CE-2 containing empagliflozin (EMPA)(30 mg/kg, Boehringer-Ingelheim, Germany)for 12 weeks (DKD-EMPA), and (3) SDT fatty rats given empagliflozin diet for first 6 weeks and switched to CE-2 containing EMPA and linagliptin (LINA) (3 mg/kg, Boehringer-Ingelheim, Germany) (DKD-EMPA + LINA)

Depression Warning Signs to Watch For Depression is a big worry for those on GLP-1 meds

The Multiple Actions of GLP-1 on the process of glucose-stimulated insulin secretions